Fundraising Fox

Kevin Bitterman

Investor

Partner at Atlas Venture

Cambridge, Massachusetts

Writes $10M – $50M checks · typically $25M

About

Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.

Invests in

Biotech

Experience

  1. Atlas VenturePartnercurrent2017 — presentCambridge, MA
  2. Judo BioBoard of Directorscurrent2022 — presentCambridge, Massachusetts, United States
  3. Remix TherapeuticsBoard of Directorscurrent2019 — presentCambridge, Massachusetts, United States
  4. nChroma BioBoard of Directorscurrent2020 — presentCambridge, Massachusetts, United States
  5. Kinaset TherapeuticsBoard of Directorscurrent2020 — presentBoston, Massachusetts, United States
  6. Disc MedicineBoard Of Directorscurrent2017 — presentCambridge, MA
  7. Isabella Stewart Gardner MuseumMember Board of Trusteescurrent2017 — presentBoston, Massachusetts, United States
  8. Mariana OncologyBoard of Directors2021 — 2024Cambridge, Massachusetts, United States
  9. New England Venture Capital AssociationBoard Member2013 — 2023Greater Boston Area
  10. Akero TherapeuticsBoard of Directors2018 — 2021Cambridge, MA
  11. Navitor PharmaceuticalsBoard of Directors2017 — 2020Cambridge, MA
  12. Editas MedicineBoard of Directors2014 — 2018Cambridge, MA
  13. Editas MedicineFounding CEO2013 — 2014Cambridge, MA
  14. Morphic TherapeuticBoard of Directors2015 — 2017Waltham, MA
  15. Morphic TherapeuticFounding CEO2014 — 2015Greater Boston Area
  16. Vets First ChoiceBoard of Directors2012 — 2017
  17. Neuronetics, Inc.Board of Directors2011 — 2017
  18. Polaris PartnersPartner2004 — 2017Greater Boston Area
  19. Kala PharmaceuticalsBoard of Directors2009 — 2017
  20. Taris BiomedicalBoard of Directors2008 — 2017

Education

  1. Harvard Medical SchoolPh.D., Genetics1999 — 2004
  2. Rutgers UniversityBA, Biology1995 — 1999

Skills & more

Venture Capital37Biotechnology72Medical Devices13Lifesciences41Technology Transfer25Commercialization58Molecular Biology5Biopharmaceuticals45Drug Discovery15Clinical Development9Clinical Trials4Genomics3
+12 moreCell BiologyStart-upsImmunologyVaccinesOncologyInfectious DiseasesDrug DevelopmentBiomarkersPharmaceutical IndustryFDARegulatory AffairsBiochemistry

From Kevin's professional profile.

Same school

Shared employers

Deals · 9

Renasant BioBoard seat

via Atlas Venture · filed Jul 2025 · $30M raise

Gro BiosciencesBoard seat

via Atlas Venture · filed Jul 2024 · $60.4M raise

Chroma Medicine, Inc.Board seat

via Atlas Venture · filed Sep 2023 · $135M raise

Navitor PharmaceuticalsBoard seat

via Atlas Venture · filed May 2020 · $20.2M raise

Akero Therapeutics, Inc.Board seat

via Atlas Venture · filed Dec 2018 · $45.5M raise

Morphic Holding, Inc.Board seat

via Atlas Venture · filed Jul 2016 · $51.5M raise

KALA BIOBoard seat

via Atlas Venture · filed Aug 2015 · $7M raise

Direct Vet MarketingBoard seat

via Atlas Venture · filed Jul 2015 · $52.3M raise

NeuroneticsBoard seat

via Atlas Venture · filed May 2015 · $34.3M raise

press ↗

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Atlas Venture

Network1

Investors connected to Kevin in public investor directories — a warm-intro map.